Search

Your search keyword '"Leemans, C. René"' showing total 847 results
Start Over Author "Leemans, C. René" Publication Type Academic Journals
847 results on '"Leemans, C. René"'

3. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification

Author

Zeng, Peter YF, Cecchini, Matthew J, Barrett, John W, Shammas-Toma, Matthew, De Cecco, Loris, Serafini, Mara S, Cavalieri, Stefano, Licitra, Lisa, Hoebers, Frank, Brakenhoff, Ruud H, Leemans, C René, Scheckenbach, Kathrin, Poli, Tito, Wang, Xiaowei, Liu, Xinyi, Laxague, Francisco, Prisman, Eitan, Poh, Catherine, Bose, Pinaki, Dort, Joseph C, Shaikh, Mushfiq H, Ryan, Sarah EB, Dawson, Alice, Khan, Mohammed I, Howlett, Christopher J, Stecho, William, Plantinga, Paul, da Silva, Sabrina Daniela, Hier, Michael, Khan, Halema, MacNeil, Danielle, Mendez, Adrian, Yoo, John, Fung, Kevin, Lang, Pencilla, Winquist, Eric, Palma, David A, Ziai, Hedyeh, Amelio, Antonio L, Li, Shawn S-C, Boutros, Paul C, Mymryk, Joe S, and Nichols, Anthony C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Prevention, Infectious Diseases, Precision Medicine, Radiation Oncology, Digestive Diseases, Sexually Transmitted Infections, Dental/Oral and Craniofacial Disease, Good Health and Well Being, Humans, Papillomavirus Infections, Retrospective Studies, Neoplasm Recurrence, Local, Oropharyngeal Neoplasms, Squamous Cell Carcinoma of Head and Neck, Prognosis, Biomarkers, Human Papillomavirus Viruses, Head and Neck Neoplasms, Papillomaviridae, Head and neck squamous cell carcinoma, Transcriptomics, Cancer immunology, HPV, De-escalation, Clinical Sciences, Public Health and Health Services, Clinical sciences, Epidemiology
Abstract

BackgroundThere is significant interest in treatment de-escalation for human papillomavirus-associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients given the generally favourable prognosis. However, 15-30% of patients recur after primary treatment, reflecting a need for improved risk-stratification tools. We sought to develop a molecular test to risk stratify HPV+ OPSCC patients.MethodsWe created an immune score (UWO3) associated with survival outcomes in six independent cohorts comprising 906 patients, including blinded retrospective and prospective external validations. Two aggressive radiation de-escalation cohorts were used to assess the ability of UWO3 to identify patients who recur. Multivariate Cox models were used to assess the associations between the UWO3 immune class and outcomes.FindingsA three-gene immune score classified patients into three immune classes (immune rich, mixed, or immune desert) and was strongly associated with disease-free survival in six datasets, including large retrospective and prospective datasets. Pooled analysis demonstrated that the immune rich group had superior disease-free survival compared to the immune desert (HR = 9.0, 95% CI: 3.2-25.5, P = 3.6 × 10-5) and mixed (HR = 6.4, 95% CI: 2.2-18.7, P = 0.006) groups after adjusting for age, sex, smoking status, and AJCC8 clinical stage. Finally, UWO3 was able to identify patients from two small treatment de-escalation cohorts who remain disease-free after aggressive de-escalation to 30 Gy radiation.InterpretationWith additional prospective validation, the UWO3 score could enable biomarker-driven clinical decision-making for patients with HPV+ OPSCC based on robust outcome prediction across six independent cohorts. Prospective de-escalation and intensification clinical trials are currently being planned.FundingCIHR, European Union, and the NIH.

Published
2022

9. The course of health-related quality of life in the first 2 years after a diagnosis of head and neck cancer: the role of personal, clinical, psychological, physical, social, lifestyle, disease-related, and biological factors

Author

Verdonck-de Leeuw, Irma M., Korsten, Laura H.A., van Nieuwenhuizen, Annette, Baatenburg de Jong, Rob J., Brakenhoff, Ruud H., Buffart, Laurien M., Lamers, Femke, Langendijk, Johannes A., Leemans, C. René, Smit, Jan H., Sprangers, Mirjam A., Takes, Robert P., Terhaard, Chris H. J., Lissenberg-Witte, Birgit I., and Jansen, Femke

Published
2023
Full Text
View/download PDF

12. Head and neck squamous cell carcinoma

Author

Johnson, Daniel E, Burtness, Barbara, Leemans, C René, Lui, Vivian Wai Yan, Bauman, Julie E, and Grandis, Jennifer R

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Rare Diseases, Sexually Transmitted Infections, Dental/Oral and Craniofacial Disease, Infectious Diseases, Clinical Research, Cancer, Digestive Diseases, Good Health and Well Being, Human papillomavirus 16, Humans, Papillomavirus Infections, Squamous Cell Carcinoma of Head and Neck, Tobacco Use, Clinical Sciences, Clinical sciences
Abstract

Most head and neck cancers are derived from the mucosal epithelium in the oral cavity, pharynx and larynx and are known collectively as head and neck squamous cell carcinoma (HNSCC). Oral cavity and larynx cancers are generally associated with tobacco consumption, alcohol abuse or both, whereas pharynx cancers are increasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16. Thus, HNSCC can be separated into HPV-negative and HPV-positive HNSCC. Despite evidence of histological progression from cellular atypia through various degrees of dysplasia, ultimately leading to invasive HNSCC, most patients are diagnosed with late-stage HNSCC without a clinically evident antecedent pre-malignant lesion. Traditional staging of HNSCC using the tumour-node-metastasis system has been supplemented by the 2017 AJCC/UICC staging system, which incorporates additional information relevant to HPV-positive disease. Treatment is generally multimodal, consisting of surgery followed by chemoradiotherapy (CRT) for oral cavity cancers and primary CRT for pharynx and larynx cancers. The EGFR monoclonal antibody cetuximab is generally used in combination with radiation in HPV-negative HNSCC where comorbidities prevent the use of cytotoxic chemotherapy. The FDA approved the immune checkpoint inhibitors pembrolizumab and nivolumab for treatment of recurrent or metastatic HNSCC and pembrolizumab as primary treatment for unresectable disease. Elucidation of the molecular genetic landscape of HNSCC over the past decade has revealed new opportunities for therapeutic intervention. Ongoing efforts aim to integrate our understanding of HNSCC biology and immunobiology to identify predictive biomarkers that will enable delivery of the most effective, least-toxic therapies.

Published
2020

19. Study retention and attrition in a longitudinal cohort study including patient-reported outcomes, fieldwork and biobank samples: results of the Netherlands quality of life and Biomedical cohort study (NET-QUBIC) among 739 head and neck cancer patients and 262 informal caregivers

Author

Jansen, Femke, Brakenhoff, Ruud H., Baatenburg de Jong, Rob J., Langendijk, Johannes A., Leemans, C. René, Takes, Robert P., Terhaard, Chris H. J., Smit, Jan H., and Verdonck-de Leeuw, Irma M.

Published
2022
Full Text
View/download PDF

21. Architectural dysplasia in surgical margins and the risk of local relapse in oral cancer.

Author

Nauta, Irene H., Peferoen, Laura A. N., Brakenhoff, Ruud H., Leemans, C. René, and Bloemena, Elisabeth

Subjects
SQUAMOUS cell carcinoma, CANCER relapse, SURGICAL margin, DYSPLASIA, ORAL cancer
Abstract

Background: A major challenge in the clinical management of oral cavity squamous cell carcinoma is local relapse. Even when surgical margins are tumor‐free, local relapses occur frequently, and relapse prediction by histology remains suboptimal. In leukoplakia, an oral potentially malignant disorder, the presence of architectural dysplasia is a critical risk factor for malignant transformation. This study aimed to investigate whether the presence of architectural dysplasia in oral cavity squamous cell carcinoma surgical margins is a risk factor for local relapse. Methods: Hematoxylin and eosin‐stained slides of resection margins from a consecutive cohort of surgically treated patients diagnosed with stage I–IV oral cavity squamous cell carcinoma between 2008 and 2014 were assessed for the presence of architectural dysplasia (N = 311). Five‐year local relapse‐free survival rates of oral cavity squamous cell carcinoma with architectural dysplasia were compared to those of oral cavity squamous cell carcinoma without architectural dysplasia. Results: In total, 92 of 311 (29.6%) of oral cavity squamous cell carcinoma displayed architectural dysplasia in the margins. The presence of architectural dysplasia was associated with higher patient age, female sex, less pack years, lower cT‐stage, and a cohesive tumor growth pattern. In oral cavity squamous cell carcinomas with architectural dysplasia, postoperative (chemo)radiotherapy was less often indicated compared with oral cavity squamous cell carcinoma without architectural dysplasia (19.5% vs. 36.1%, p = 0.009). Five‐year local relapse‐free survival was significantly lower in oral cavity squamous cell carcinoma with architectural dysplasia than in oral cavity squamous cell carcinoma without architectural dysplasia (83.1% vs. 94.9%, p = 0.017). Conclusions: Oral cavity squamous cell carcinoma arising in the background of architectural dysplasia displays relatively favorable clinical and histopathological characteristics. Nonetheless, the presence of architectural dysplasia in oral cavity squamous cell carcinoma surgical margins is associated with a higher risk of local relapse, indicating its clinical relevance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Cost-utility and cost-effectiveness of a guided self-help head and neck exercise program for patients treated with total laryngectomy: Results of a multi-center randomized controlled trial

Author

Jansen, Femke, Coupé, Veerle M.H., Eerenstein, Simone E.J., Cnossen, Ingrid C., van Uden-Kraan, Cornelia F., de Bree, Remco, Doornaert, Patricia, Halmos, György B., Hardillo, José A.U., van Hinte, Gerben, Honings, Jimmie, Leemans, C. René, and Verdonck-de Leeuw, Irma M.

Published
2021
Full Text
View/download PDF

32. European white paper: oropharyngeal dysphagia in head and neck cancer

Author

Baijens, Laura W. J., Walshe, Margaret, Aaltonen, Leena-Maija, Arens, Christoph, Cordier, Reinie, Cras, Patrick, Crevier-Buchman, Lise, Curtis, Chris, Golusinski, Wojciech, Govender, Roganie, Eriksen, Jesper Grau, Hansen, Kevin, Heathcote, Kate, Hess, Markus M., Hosal, Sefik, Klussmann, Jens Peter, Leemans, C. René, MacCarthy, Denise, Manduchi, Beatrice, Marie, Jean-Paul, Nouraei, Reza, Parkes, Claire, Pflug, Christina, Pilz, Walmari, Regan, Julie, Rommel, Nathalie, Schindler, Antonio, Schols, Annemie M. W. J., Speyer, Renee, Succo, Giovanni, Wessel, Irene, Willemsen, Anna C. H., Yilmaz, Taner, and Clavé, Pere

Published
2021
Full Text
View/download PDF

33. Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus

Author

Mehanna, Hisham, Hardman, John C, Shenson, Jared A, Abou-Foul, Ahmad K, Topf, Michael C, AlFalasi, Mohammad, Chan, Jason Y K, Chaturvedi, Pankaj, Chow, Velda Ling Yu, Dietz, Andreas, Fagan, Johannes J, Godballe, Christian, Golusiński, Wojciech, Homma, Akihiro, Hosal, Sefik, Iyer, N Gopalakrishna, Kerawala, Cyrus, Koh, Yoon Woo, Konney, Anna, Kowalski, Luiz P, Kraus, Dennis, Kuriakose, Moni A, Kyrodimos, Efthymios, Lai, Stephen Y, Leemans, C Rene, Lennon, Paul, Licitra, Lisa, Lou, Pei-Jen, Lyons, Bernard, Mirghani, Haitham, Nichols, Anthonny C, Paleri, Vinidh, Panizza, Benedict J, Parente Arias, Pablo, Patel, Mihir R, Piazza, Cesare, Rischin, Danny, Sanabria, Alvaro, Takes, Robert P, Thomson, David J, Uppaluri, Ravindra, Wang, Yu, Yom, Sue S, Zhu, Yi-ming, Porceddu, Sandro V, de Almeida, John R, Simon, Chrisian, and Holsinger, F Christopher

Published
2020
Full Text
View/download PDF

36. Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial

Author

van der Hout, Anja, van Uden-Kraan, Cornelia F, Holtmaat, Karen, Jansen, Femke, Lissenberg-Witte, Birgit I, Nieuwenhuijzen, Grard A P, Hardillo, José A, Baatenburg de Jong, Robert J, Tiren-Verbeet, Nicolette L, Sommeijer, Dirkje W, de Heer, Koen, Schaar, Cees G, Sedee, Robert-Jan E, Bosscha, Koop, van den Brekel, Michiel W M, Petersen, Japke F, Westerman, Matthijs, Honings, Jimmie, Takes, Robert P, Houtenbos, Ilse, van den Broek, Wim T, de Bree, Remco, Jansen, Patricia, Eerenstein, Simone E J, Leemans, C René, Zijlstra, Josée M, Cuijpers, Pim, van de Poll-Franse, Lonneke V, and Verdonck-de Leeuw, Irma M

Published
2020
Full Text
View/download PDF

44. Mental healthcare utilization among head and neck cancer patients: A longitudinal cohort study.

Author

Jansen, Femke, Lissenberg‐Witte, Birgit I., Hardillo, Jose A., Takes, Robert P., de Bree, Remco, Lamers, Femke, Langendijk, Johannes A., Leemans, C. René, and Verdonck‐de Leeuw, Irma M.

Subjects
HEAD & neck cancer, MENTAL health services, MEDICAL care use, SOCIAL anxiety, CANCER patients, GENERALIZED estimating equations, SENSATION seeking, COHORT analysis
Abstract

Objective: To investigate utilization of mental healthcare among head and neck cancer (HNC) patients from diagnosis to 2 years after treatment, in relation to psychological symptoms, mental disorders, need for mental healthcare, and sociodemographic, clinical and personal factors. Methods: Netherlands Quality of life and Biomedical Cohort study data as measured before treatment, at 3 and 6 months, and at 1 and 2 years after treatment was used (n = 610). Data on mental healthcare utilization (iMCQ), psychological symptoms (Hospital Anxiety and Depression Scale, Cancer Worry Scale), mental disorders (CIDI interview), need for mental healthcare (Supportive Care Needs Survey Short‐Form 34, either as continuous outcome indicating the level of need or dichotomized into unmet need (yes/no)) and several sociodemographic, clinical and personal factors were collected. Factors associated with mental healthcare utilization were investigated using generalized estimating equations (p < 0.05). Results: Of all HNC patients, 5%–9% used mental healthcare per timepoint. This was 4%–14% in patients with mild‐severe psychological symptoms, 4%–17% in patients with severe psychological symptoms, 15%–35% in patients with a mental disorder and 5%–16% in patients with an unmet need for mental healthcare. Among all patients, higher symptoms of anxiety, a higher need for mental healthcare, lower age, higher disease stage, lower self‐efficacy and higher social support seeking were significantly associated with mental healthcare utilization. Conclusion: Mental health care utilization among HNC patients is limited, and is related to psychological symptoms, need for mental healthcare, and sociodemographic, clinical and personal factors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirus–Positive Oropharyngeal Carcinoma

Author

Cavalieri, Stefano, Serafini, Mara S., Carenzo, Andrea, Canevari, Silvana, Brakenhoff, Ruud H., Leemans, C. René, Nauta, Irene H., Hoebers, Frank, van den Hout, Mari F. C. M., Scheckenbach, Kathrin, Hoffmann, Thomas K., Ardighieri, Laura, Poli, Tito, Quattrone, Pasquale, Locati, Laura D., Licitra, Lisa, and De Cecco, Loris

Published
2021
Full Text
View/download PDF

49. Predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma

Author

Martens, Roland M., Koopman, Thomas, Noij, Daniel P., Pfaehler, Elisabeth, Übelhör, Caroline, Sharma, Sughandi, Vergeer, Marije R., Leemans, C. René, Hoekstra, Otto S., Yaqub, Maqsood, Zwezerijnen, Gerben J., Heymans, Martijn W., Peeters, Carel F. W., de Bree, Remco, de Graaf, Pim, Castelijns, Jonas A., and Boellaard, Ronald

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results